PriceTargets.com logo

Day One Biopharmaceuticals - DAWN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $32.29
  • Forecasted Upside: 317.40%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 1 Strong Buy Ratings
$7.74 As of 04/29/2025 03:15 PM ET
▼ -0.005 (-0.06%)

This chart shows the closing price for DAWN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
MarApr$7.74Closing price on 04/28/25:
Get New Day One Biopharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DAWN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DAWN

Analyst Price Target is $32.29
▲ +317.40% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Day One Biopharmaceuticals in the last 3 months. The average price target is $32.29, with a high forecast of $40.00 and a low forecast of $25.00. The average price target represents a 317.40% upside from the last price of $7.74.

This chart shows the closing price for DAWN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
4/247/2410/241/254/255/26$4.70$14$22$31$40Closing price on 04/28/25: $7.74High$40.00Average$32.29Low$25.00




Current Consensus is Buy

The current consensus among 8 contributing investment analysts is to buy stock in Day One Biopharmaceuticals. This rating has held steady since October 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
11/6/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/4/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/4/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/2/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2024
  • 1 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2025
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/30/2025
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/29/2025

Latest Recommendations

  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/3/2025HC WainwrightReiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
3/25/2025The Goldman Sachs GroupLower TargetBuy ➝ Buy$39.00 ➝ $27.00
3/5/2025JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$39.00 ➝ $34.00
2/26/2025WedbushReiterated RatingOutperform ➝ Outperform$32.00 ➝ $32.00
2/26/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
2/26/2025HC WainwrightLower TargetBuy ➝ Buy$40.00 ➝ $36.00
2/10/2025The Goldman Sachs GroupLower TargetBuy ➝ Buy$48.00 ➝ $43.00
1/13/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$33.00 ➝ $33.00
1/7/2025Bank of AmericaLower TargetBuy ➝ Buy$28.00 ➝ $25.00
11/4/2024TD CowenUpgradeStrong-Buy
10/31/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$33.00 ➝ $33.00
10/31/2024HC WainwrightReiterated RatingBuy ➝ Buy$40.00 ➝ $40.00
10/9/2024Needham & Company LLCBoost TargetBuy ➝ Buy$32.00 ➝ $33.00
8/6/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$38.00 ➝ $36.00
8/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$40.00 ➝ $40.00
8/1/2024Bank of AmericaUpgradeUnderperform ➝ Buy$11.00 ➝ $24.00
7/30/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$33.00 ➝ $33.00
7/26/2024HC WainwrightReiterated RatingBuy ➝ Buy$40.00 ➝ $40.00
7/25/2024WedbushReiterated RatingOutperform$33.00
7/8/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$40.00 ➝ $40.00
6/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$40.00 ➝ $40.00
6/19/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$33.00 ➝ $33.00
5/7/2024WedbushReiterated RatingOutperform$33.00
5/7/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$33.00
5/7/2024HC WainwrightLower TargetBuy ➝ Buy$50.00 ➝ $40.00
4/24/2024WedbushReiterated RatingOutperform$33.00
4/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00
4/24/2024Needham & Company LLCBoost TargetBuy ➝ Buy$30.00 ➝ $33.00
4/22/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$32.00 ➝ $36.00
3/26/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$40.00
2/28/2024Piper SandlerLower TargetOverweight ➝ Overweight$45.00 ➝ $40.00
2/27/2024The Goldman Sachs GroupLower TargetBuy ➝ Buy$50.00 ➝ $44.00
2/27/2024OppenheimerReiterated RatingMarket Perform ➝ Market Perform
11/7/2023WedbushLower TargetOutperform ➝ Outperform$39.00 ➝ $35.00
11/7/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$34.00
9/12/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$34.00
9/12/2023WedbushReiterated RatingOutperform ➝ Outperform$38.00
8/8/2023WedbushReiterated RatingOutperform$38.00
8/8/2023Needham & Company LLCReiterated RatingBuy$34.00
8/8/2023The Goldman Sachs GroupLower TargetBuy ➝ Buy$63.00 ➝ $54.00
8/8/2023HC WainwrightReiterated RatingBuy ➝ Buy$50.00
6/5/2023HC WainwrightBoost Target$45.00 ➝ $50.00
4/25/2023Bank of AmericaDowngradeBuy ➝ Underperform
4/5/2023Needham & Company LLCLower TargetBuy$48.00 ➝ $44.00
3/7/2023HC WainwrightReiterated RatingBuy$45.00
3/7/2023Needham & Company LLCReiterated RatingBuy$48.00
2/8/2023Capital One FinancialInitiated CoverageOverweight$40.00
2/2/2023OppenheimerInitiated CoverageMarket Perform
1/9/2023The Goldman Sachs GroupBoost TargetBuy$45.00 ➝ $62.00
1/9/2023HC WainwrightBoost TargetBuy$35.00 ➝ $45.00
1/8/2023Piper SandlerBoost TargetOverweight$40.00 ➝ $45.00
12/15/2022HC WainwrightInitiated CoverageBuy$35.00
12/14/2022Needham & Company LLCInitiated CoverageBuy$40.00
12/5/2022The Goldman Sachs GroupInitiated CoverageBuy$45.00
12/1/2022Bank of AmericaInitiated CoverageBuy$34.00
6/20/2022Piper SandlerBoost TargetOverweight$35.00 ➝ $40.00
6/13/2022WedbushBoost TargetOutperform$32.00 ➝ $35.00
6/21/2021JPMorgan Chase & Co.Initiated CoverageOverweight$38.00
6/21/2021WedbushInitiated CoverageOutperform$30.00
6/21/2021CowenInitiated CoverageOutperform
6/21/2021Piper SandlerInitiated CoverageOverweight$44.00
(Data available from 4/29/2020 forward)

News Sentiment Rating

0.82 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 8 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2024
  • 9 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2024
  • 18 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2024
  • 11 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2024
  • 5 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2025
  • 8 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
2/28/2025
  • 8 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
3/30/2025
  • 13 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
4/29/2025

Current Sentiment

  • 13 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Day One Biopharmaceuticals logo
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Read More

Today's Range

Now: $7.74
Low: $7.63
High: $7.84

50 Day Range

MA: $8.27
Low: $6.71
High: $12.43

52 Week Range

Now: $7.74
Low: $6.41
High: $18.07

Volume

492,640 shs

Average Volume

1,060,479 shs

Market Capitalization

$783.97 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Day One Biopharmaceuticals?

The following equities research analysts have issued research reports on Day One Biopharmaceuticals in the last year: Bank of America Co., HC Wainwright, JPMorgan Chase & Co., Needham & Company LLC, Piper Sandler, TD Cowen, The Goldman Sachs Group, Inc., and Wedbush.
View the latest analyst ratings for DAWN.

What is the current price target for Day One Biopharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Day One Biopharmaceuticals in the last year. Their average twelve-month price target is $32.29, suggesting a possible upside of 317.4%. Piper Sandler has the highest price target set, predicting DAWN will reach $40.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $25.00 for Day One Biopharmaceuticals in the next year.
View the latest price targets for DAWN.

What is the current consensus analyst rating for Day One Biopharmaceuticals?

Day One Biopharmaceuticals currently has 7 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DAWN will outperform the market and that investors should add to their positions of Day One Biopharmaceuticals.
View the latest ratings for DAWN.

What other companies compete with Day One Biopharmaceuticals?

Other companies that are similar to Day One Biopharmaceuticals include Merus, Crinetics Pharmaceuticals, Scholar Rock, Akero Therapeutics and Viking Therapeutics. Learn More about companies similar to Day One Biopharmaceuticals.

How do I contact Day One Biopharmaceuticals' investor relations team?

Day One Biopharmaceuticals' physical mailing address is 395 OYSTER POINT BLVD STE 217, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is 650-484-0899 and its investor relations email address is hans@lifesciadvisors.com. The official website for Day One Biopharmaceuticals is dayonebio.com. Learn More about contacing Day One Biopharmaceuticals investor relations.





Receive Day One Biopharmaceuticals News & Ratings Daily
Sign up to receive the latest news and ratings for Day One Biopharmaceuticals and its competitors with PriceTargets.com’s free daily newsletter.